Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471444 · ClinicalTrials.gov registry record · Phase 3
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT01471444: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT01471444 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 256 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01471444, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients with AML or MDS. The safety of this combination therapy will also be studied.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thymoglobulin
- DRUG Clofarabine
- PROCEDURE Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2011-11-02 |
| Est. Completion | 2020-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471444
The ClinicalTrials.gov registry entry for NCT01471444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01471444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471444 about?
NCT01471444 is a clinical study titled "Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients with AML or MDS. The safety of this combination therapy will also be st...
What is the current status of trial NCT01471444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2011-11-02. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT01471444?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Thymoglobulin (DRUG), Clofarabine (DRUG), Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01471444?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.